Medical Design Briefs - June 2023 - 18

Dynamic cell imaging of immune cells in inflamed breast tissue enhances
cellular contrast by capturing residual microscopic intracellular movements
in freshly excised tissue. (Credit: Aquyre Biosciences)
Fighting Cancer
with Real-Time Diagnostics
I
nadequate real-time tissue assessment
of biopsies from different cell
types, like cancer cells, immune cells,
granuloma, and others, forces proceduralists,
such as bronchoscopists
and radiologists, to choose between intraprocedural
partial tissue adequacy assessment,
rapid on-site evaluation
(ROSE), or sending tissue samples for
full pathology review. Neither truly answers
the question, " Do we have enough
cells to submit to pathology for the best
chance of a conclusive diagnosis? " This
can lead to prolonged delay for patient
results, the need for a redo procedure,
and potential delays for treatment options
for the patient.
Consider lung biopsies, which are excised
from patients and then sent to the
laboratory for advanced cancer testing.
These tests require that patients have an
adequate amount of high-quality tissue
to conduct advanced tests such as EGFR,
kRas, or PD-1/PDL-1. To collect these
biopsies, transthoracic needle biopsy
(TTNA) is commonly used, which requires
a needle to be inserted through
the chest wall from outside the body.
The risk of a collapsed lung (pneumothorax)
can result in an average of 20
percent of procedures. Navigational
18
bronchoscopy has emerged as a technology
to collect lung biopsies with a lower
risk of complications.
A better solution would be to assess tissue
adequacy intraprocedurally, to interrogate
and image the biopsy in its entirety,
to determine: Do we have the tissue?
What exactly are we looking at (cancer
cells, immune cells, granuloma)? And,
do we have enough cells to submit to
pathology to gain the best chance of a
conclusive diagnosis? The results would
allow clinicians intraprocedural identification
and interpretation to properly
assess tissue samples for adequacy.
Real-Time Diagnostics
Such a solution has recently been
cleared by the FDA. Developed by Aquyre
Biosciences, Inc. after a decade of research,
CelTivity™ provides
real-time
cancer diagnostics of freshly excised cells
and tissue in the operating room and private
practice labs, effectively expanding
advanced diagnosis capabilities.
" Integrating digital images, data lakes,
machine learning, and artificial intelligence,
CelTivity utilizes two proprietary
technologies integrated within one
exam, producing high-resolution images
that delineate tissue microstructures and
www.medicaldesignbriefs.com
intracellular activity up to 1 µm in 3D, "
says Bertrand Le Conte de Poly, CEO of
Aquyre Biosciences. " These technologies
are full-field optical coherence tomography
(FFOCT), and dynamic cell
imaging (DCI). Of significance, is that
these diagnostic results are available
within two minutes. The freshly excised
sample can then be sent to pathology,
along with the CelTivity data. Moreover,
tissue depth exploration can be achieved
at 150 μm below the tissue surface with
no cutting, staining, chemicals, or sectioning
required. "
Full-Field Optical Coherence
Tomography
The CelTivity Full-Field OCT performs
noninvasive, high-resolution optical
slicing beneath the tissue surface.
The full-field approach offers great potential
in imaging of samples to assist fast
diagnostic of cellular and morphological
scale pathologies, such as cancer. It consists
of an interference microscope, or
more precisely, a classic Michelson interferometer
with a microscope objective in
each arm. The Michelson interferometer
produces interference fringes by
splitting a beam of light so that one
beam strikes a fixed mirror and the othMedical
Design Briefs, June 2023
http://www.medicaldesignbriefs.com
Medical Design Briefs - June 2023

Table of Contents for the Digital Edition of Medical Design Briefs - June 2023
